Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Koshi Akahane"'
Autor:
Kazuya Takahashi, Thao Thu Thi Nguyen, Atsushi Watanabe, Hiroki Sato, Kinuko Saito, Minori Tamai, Daisuke Harama, Shin Kasai, Koshi Akahane, Kumiko Goi, Keiko Kagami, Masako Abe, Chiaki Komatsu, Yasuhiro Maeda, Kanji Sugita, Takeshi Inukai
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Background Adhesion of cancer cells to extracellular matrix laminin through the integrin superfamily reportedly induces drug resistance. Heterodimers of integrin α6 (CD49f) with integrin β1 (CD29) or β4 (CD104) are major functional recept
Externí odkaz:
https://doaj.org/article/666d4fe3ec04411e8df3352ceae1c942
Autor:
Haruka Hiroki, Yuko Ishii, Jinhua Piao, Yui Namikawa, Mitsuko Masutani, Hiroaki Honda, Koshi Akahane, Takeshi Inukai, Tomohiro Morio, Masatoshi Takagi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract BCR/ABL1 causes dysregulated cell proliferation and is responsible for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). In addition to the deregulatory effects of its kinase acti
Externí odkaz:
https://doaj.org/article/6de88a99d65c420ba53c372906669dcd
Autor:
Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S. Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Minori Tamai, Thao T. T. Nguyen, Koshi Akahane, Takeshi Inukai, Leif Stenke, Daniel Salamon
Publikováno v:
Cell Death and Disease, Vol 12, Iss 10, Pp 1-13 (2021)
Abstract Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targe
Externí odkaz:
https://doaj.org/article/b3f98bbdd0f14217ba00f833de4eaaa3
Autor:
Daisuke Harama, Takashi Yahata, Keiko Kagami, Masako Abe, Norie Ando, Shin Kasai, Minori Tamai, Koshi Akahane, Takeshi Inukai, Nobutaka Kiyokawa, Abd Aziz Ibrahim, Kiyoshi Ando, Kanji Sugita
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-14 (2021)
Abstract The long-term prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is still unsatisfactory even after the emergence of tyrosine kinase inhibitors (TKIs) against chimeric BCR-ABL, and this is associated with t
Externí odkaz:
https://doaj.org/article/2156dba5f82d4456a3ea4c71de9a68ce
Autor:
Shinobu Tsuzuki, Takahiko Yasuda, Hiroaki Goto, Naoko Maeda, Koshi Akahane, Takeshi Inukai, Hideyuki Yamamoto, Sivasundaram Karnan, Akinobu Ota, Toshinori Hyodo, Hiroyuki Konishi, Yoshitaka Hosokawa, Hitoshi Kiyoi, Fumihiko Hayakawa
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is an intractable disease and most cases harbor genetic alterations that activate JAK or ABL signaling. The commonest subtype of Ph-like ALL exhibits a CRLF2 gene rearrangement t
Externí odkaz:
https://doaj.org/article/514652542c624b93836c399d9da87c53
Autor:
Minori Tamai, Meixian Huang, Keiko Kagami, Masako Abe, Shinpei Somazu, Tamao Shinohara, Daisuke Harama, Atsushi Watanabe, Koshi Akahane, Kumiko Goi, Kanji Sugita, Hiroaki Goto, Masayoshi Minegishi, Shotaro Iwamoto, Takeshi Inukai
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The genetic variants of the ARID5B gene have recently been reported to be associated with disease susceptibility and treatment outcome in childhood acute lymphoblastic leukemia (ALL). However, few studies have explored the associa
Externí odkaz:
https://doaj.org/article/82ce8da79f7c4918acc9b98aacd50f66
ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry
Autor:
Lu Wang, Tze King Tan, Adam D. Durbin, Mark W. Zimmerman, Brian J. Abraham, Shi Hao Tan, Phuong Cao Thi Ngoc, Nina Weichert-Leahey, Koshi Akahane, Lee N. Lawton, Jo Lynne Rokita, John M. Maris, Richard A. Young, A. Thomas Look, Takaomi Sanda
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Polymorphisms in LMO1 are associated with increased susceptibility to develop neuroblastoma. Here, the authors show that LMO1 directly induces the transcription factor ASCL1, which regulates the differentiation of neurons, demonstrating that ASCL1 is
Externí odkaz:
https://doaj.org/article/e6eb4888c5884e66bc019c078ad386b1
Autor:
Atsushi Watanabe, Takeshi Inukai, Keiko Kagami, Masako Abe, Masatoshi Takagi, Takashi Fukushima, Hiroko Fukushima, Toru Nanmoku, Kiminori Terui, Tatsuya Ito, Tsutomu Toki, Etsuro Ito, Junya Fujimura, Hiroaki Goto, Mikiya Endo, Thomas Look, Mark Kamps, Masayoshi Minegishi, Junko Takita, Toshiya Inaba, Hiroyuki Takahashi, Akira Ohara, Daisuke Harama, Tamao Shinohara, Shinpei Somazu, Hiroko Oshiro, Koshi Akahane, Kumiko Goi, Kanji Sugita
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5274-5288 (2019)
Abstract t(17;19)(q21‐q22;p13), responsible for TCF3‐HLF fusion, is a rare translocation in childhood B‐cell precursor acute lymphoblastic leukemia(BCP‐ALL). t(1;19)(q23;p13), producing TCF3‐PBX1 fusion, is a common translocation in childho
Externí odkaz:
https://doaj.org/article/1f2cd76742cf40039a4a5f75ed9afda2
Autor:
Meixian Huang, Takeshi Inukai, Kunio Miyake, Yoichi Tanaka, Keiko Kagami, Masako Abe, Hiroaki Goto, Masayoshi Minegishi, Shotaro Iwamoto, Eiji Sugihara, Atsushi Watanabe, Shinpei Somazu, Tamao Shinohara, Hiroko Oshiro, Koshi Akahane, Kumiko Goi, Kanji Sugita
Publikováno v:
Cancer Medicine, Vol 7, Iss 4, Pp 1297-1316 (2018)
Abstract Cytosine arabinoside (Ara‐C) is one of the key drugs for the treatment of acute myeloid leukemia. It is also used for consolidation therapy of acute lymphoblastic leukemia (ALL). Ara‐C is a deoxyadenosine analog and is phosphorylated to
Externí odkaz:
https://doaj.org/article/a854096ebe964816b364a64b5f2d7ffa
Autor:
Atsushi Watanabe, Kunio Miyake, Koshi Akahane, Kumiko Goi, Keiko Kagami, Hideo Yagita, Takeshi Inukai
Publikováno v:
Genes, Vol 12, Iss 6, p 864 (2021)
Immunotherapies specific for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), such as anti-CD19 chimeric antigen receptor (CAR) T-cells and blinatumomab, have dramatically improved the therapeutic outcome in refractory cases. In the anti-leuk
Externí odkaz:
https://doaj.org/article/213ae163f84d44b6918bf69e39f83c5f